While monoimmunotherapy has limited impact in several subtypes, combination approaches show promise, especially in KRAS G12C, BRAF non-V600E, and MET-amplified cases.
Precision matters.
buff.ly/AyrHAkr
#NSCLC #Immunotherapy #Oncology

🚨 Call for Papers – Special Collection! @tamedoncol.bsky.social seeks submissions on: De-escalation of Treatment in Gynecologic Cancers. 🗓️ Submit by March 18, 2026 📥 Submit:

Zolbetuximab is gaining attention as a targeted therapy for CLDN18.2-positive gastric and GEJ cancers.
This review dives into the science behind Claudin18.2 and the clinical promise of zolbetuximab, backed by SPOTLIGHT and GLOW trial data.
buff.ly/ok6eO7y
#Oncology #GastricCancer #Zolbetuximab

🧬 Article collection on @tamedoncol.bsky.social: PARPi in Gynecologic Cancers. This collection highlights research on HRR genetic landscape, PARPi outcomes, oxaliplatin sequencing in BRCA-mutated ovarian cancer, and PARPi resistance with combination strategies. 📚 Explore more

Lung cancer is varying by region in risks and traits. A new article examines carcinogens, genetic predisposition, and molecular epidemiology. We seek submissions on geographic differences in lung cancer. Deadline: Dec 31, 2025 🔗 buff.ly/JCo9lJP #CancerResearch #LungCancer #GlobalHealth

🚨Call for Papers: @tamedoncol.bsky.social invites submissions on Antibody Drug Conjugates (ADCs) in Gynecologic Cancers. Led by Dr. Angélica Nogueira Rodrigues & Dr. Rowan Miller, this collection spotlights innovative ADC research in gynecologic oncology. 📥 Submit your work. buff.ly/RhdEIHX

🌟 Discover our top-cited article at @tamedoncol.bsky.social on aberrant DNA methylation in cancer. This review delves into epigenetic influences from BRCA1 to ctDNA, highlighting diagnostic, prognostic, and therapeutic impacts. 📖 Read more 🌟 buff.ly/ZAp0iD3

🧬 Just launched!
The latest article collection from @tamedoncol.bsky.social dives into rare cancers with a clinical lens.
📚 Explore the collection

🌟 Most cited in its year!
Explore Diagnostic biomarkers in ovarian cancer: advances beyond CA125 and HE4 in @tamedoncol.bsky.social. This review highlights promising multivariate assays like ROMA, OVA1 & Overa that could transform early OC detection.
📖 Read the article buff.ly/49NiTuO

Our article collection on Women in @tamedoncol.bsky.social is now live!

Featuring powerful research led by women in oncology

Check it out and celebrate women driving innovation in cancer care:
journals.sagepub.com/topic/collec...

#WomenInScience #Oncology #CancerResearch #BlueSkyScience

🌟 New Special Collection! 🌟

"Navigating New Treatment Options in HR+HER2- Advanced Breast Cancer" is now open for submissions. We invite researchers and clinicians to share their insights.

🔗 Submit journals.sagepub.com/topic/collec...

Join us to improve patient care and outcomes. 🚀

I am thrilled to share that I have taken on the role of Editor for Thera Adv in Med Oncology @tamedoncol.bsky.social, succeeding my wonderful colleague, Georgia Patey. I am excited to collaborate closely with our editorial board members, authors, and readers. journals.sagepub.com/home/tam